Skip to main contentWhat happened to Peptide Sciences?
On March 6, 2026, Peptide Sciences — the largest research peptide vendor in the United States by web traffic — shut down operations without advance notice. No warning to customers, no communication to research partners, no public explanation beyond a brief shutdown notice on their website.
The scale of the disruption was substantial. Third-party analytics estimated approximately 990,000 monthly visits and $7.4 million per month in revenue at closure. Over more than a decade of operations, Peptide Sciences had built a catalog exceeding 190 research compounds spanning growth hormone secretagogues, metabolic peptides, tissue repair factors, cognitive research compounds, and longevity peptides. For a large portion of the research community, they were the primary supplier.
The operational fallout was immediate. Ongoing orders were canceled. Customer service channels went dark within days. Researchers reported receiving no email notification, no fulfillment timeline, and no guidance on refund procedures. Forum threads and social media channels filled with researchers attempting to reach the company through any available path. The abrupt nature of the closure — with no wind-down period and no communication infrastructure — is itself informative about the circumstances that drove it.
For academic laboratories with grant-funded projects on fixed timelines, the disruption was more than logistical. Qualifying a new supplier and validating compound equivalence takes weeks to months. Labs in the middle of longitudinal studies faced the choice of pausing active experiments or accepting unvalidated supply chain substitution. Neither option is analytically clean.
The regulatory environment preceding the shutdown is the context that makes the timing intelligible.
Why did Peptide Sciences shut down?
The closure was the end of a sequence, not an isolated event. Multiple converging pressures made continued operations increasingly untenable over the 12 months preceding the shutdown.
FDA enforcement escalation. Beginning September 2025, the FDA issued more than 50 warning letters to peptide vendors, compounding pharmacies, and adjacent businesses. These letters cited violations spanning unapproved drug distribution, misbranding, and manufacturing deficiencies. The volume and pace were unprecedented for the sector. Each letter carried implicit escalation risk — injunctions, seizures, criminal referral — for non-compliance. The message from the agency was not ambiguous.
The Amino Asylum warehouse raid. In June 2025, federal agents executed a raid on the warehouse operations of Amino Asylum, a prominent research peptide vendor. Physical enforcement — not just letters — signaled that the FDA was prepared to deploy its most aggressive tools against this sector. This event is widely identified as an inflection point that caused vendors across the industry to reassess their operational exposure.
Resolution of the semaglutide shortage. In February 2025, the FDA officially resolved the semaglutide drug shortage. That resolution eliminated the legal basis under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act that had allowed compounding pharmacies and some research vendors to produce and sell GLP-1 compounds during the shortage period. GLP-1-related compounds represented significant revenue across the sector. The elimination of that regulatory window changed the risk calculus for vendors heavily weighted toward those SKUs.
The SAFE Drugs Act. Introduced in early 2026, the Strengthening and Advancing Federal Enforcement of Drugs Act proposed expanded FDA authority to pursue enforcement against entities distributing unapproved peptide products. The legislation had not passed at the time of the Peptide Sciences closure, but its introduction signaled bipartisan Congressional support for tightening oversight of the peptide market.
Quality failures and third-party testing. Finnrick Analytics and other independent testing organizations published analyses documenting quality failures across multiple vendors — including Peptide Sciences. Retatrutide counterfeits were identified circulating in the market. CJC-1295 purity scores were poor across several suppliers. These findings directly undermined vendor quality assurances and created additional legal exposure, providing potential misbranding evidence to any agency investigating compliance.
Taken together, the pattern is a proactive closure to avoid what was coming rather than waiting for enforcement to arrive.
What does this mean for the research peptide market?
The Peptide Sciences exit removed the market's highest-traffic vendor overnight, redirecting roughly one million monthly visitors toward alternative suppliers. The secondary effects are structural.
Immediate supply disruption. Researchers with active longitudinal studies faced abrupt supply chain failures at the worst possible time — mid-study, with no wind-down period. Switching vendors mid-study introduces batch consistency variables that can compromise data integrity across time points. For institutions with procurement agreements, administrative vendor qualification processes added weeks to an already urgent timeline.
Heightened scrutiny of supplier quality. The third-party testing data that contributed to Peptide Sciences' regulatory exposure is now being applied as a selection filter. Researchers are asking harder questions about purity verification methodology, analytical credentials of testing laboratories, and whether COA documentation represents genuine independent testing or self-certified claims. The Finnrick findings on retatrutide counterfeits and substandard CJC-1295 batches have made the research community more skeptical of marketing claims industry-wide.
Continued regulatory pressure. RFK Jr. has announced public plans for peptide reclassification that could fundamentally alter how research compounds are categorized and sold. Whether that policy materializes in specific regulatory action remains uncertain, but the directional trend is clear: the era of minimal oversight for research peptide vendors is ending. Remaining vendors operate in an environment of increasing FDA scrutiny, state-level enforcement activity, and an increasingly informed buyer base.
Market consolidation around quality signals. With the largest vendor gone, remaining suppliers are absorbing displaced demand. Vendors without adequate quality systems, supply chain infrastructure, or compliance practices face stress under increased volume. Those with documented verification processes and operational compliance are positioned to serve researchers who now treat quality documentation as a baseline procurement requirement rather than a differentiator.
The research peptide market is not contracting. Demand for high-purity research compounds from academic institutions, independent investigators, and scientific organizations remains strong. What is changing is what researchers require from their supplier to consider a procurement decision made on defensible grounds.
What should researchers look for in a peptide supplier in 2026?
In the post-Peptide Sciences environment, supplier evaluation requires applying concrete criteria — not brand familiarity or catalog size. The following represent the minimum standard for a defensible procurement decision.
Third-party Certificate of Analysis with every order. A legitimate COA accompanies every batch automatically — it is not request-required. The COA must be batch-specific: a recycled document applied across multiple production runs is a documentation failure, not compliance. Review the COA for specific batch numbers, testing dates, analyst identification, and testing laboratory contact information. For a detailed guide on what the analytical data actually means, see How to Read a Certificate of Analysis.
HPLC verification and mass spectrometry. HPLC is the quantification standard for purity; mass spectrometry provides identity confirmation. Both methods should be documented for every compound. Request the actual chromatogram images — a purity percentage without the underlying separation data is unverifiable. A deeper treatment of these methods and what they diagnose is in our article on Peptide Purity.
Endotoxin testing. Bacterial endotoxin contamination is a critical failure mode for compounds used in cell culture and in vitro assay work. Limulus Amebocyte Lysate (LAL) testing or recombinant Factor C assays detect endotoxin. Suppliers who omit this step are cutting a quality checkpoint that matters directly to the validity of cell-based experiments.
Cold-chain shipping as standard. Peptides degrade through oxidation, aggregation, and deamidation during warm transit. A compound that ships at ≥99% purity can arrive at a different purity level if not temperature-controlled during a summer shipment to a warm climate. Cold-chain packaging should be the default, not a premium add-on. Ask any prospective vendor directly: is cold-chain shipping included or separately priced?
Transparent purity standards. Research-grade compounds require ≥98% minimum, with sensitive applications demanding ≥99%. Suppliers should publish their purity thresholds and provide compound-specific analytical data to back them. Marketing claims about purity that cannot be traced to batch-level chromatographic evidence are unverified claims.
US-based operations. Domestic operations provide regulatory jurisdiction, faster shipping, and clearer dispute resolution pathways. US-based vendors face direct FDA oversight — a constraint that also functions as a quality floor.
These are not aspirational standards. They are the minimum threshold for responsible research compound procurement in a market where quality failures have documented downstream consequences for experimental validity and institutional regulatory exposure.
How is Onward Aminos different?
Onward Aminos operates on a quality framework designed to address the documented failures that characterized the broader market before and during the Peptide Sciences closure. All compounds are for research purposes only.
Onward Aminos maintains 64 research-grade compounds, each held to a minimum ≥99% purity standard verified by independent third-party analytical testing. Every order ships with a batch-specific Certificate of Analysis documenting HPLC purity quantification and mass spectrometry identity confirmation — included automatically with every shipment, not available on request.
Endotoxin testing is performed on all compounds using validated detection methods. This is a step many suppliers skip or apply selectively. For researchers running cell-based assays, endotoxin data is a quality requirement, not an optional add-on.
All shipments are cold-chain packaged as standard. Insulated containers with temperature-maintaining materials protect compound integrity from warehouse dispatch through laboratory intake. A compound that arrives degraded due to transit heat exposure is no longer what was ordered, regardless of what the pre-shipment COA stated.
Onward Aminos operates entirely within the United States. Researchers can browse the full catalog at /compounds to review compounds, pricing, and category organization.
The operating principle is documentation over marketing: independently verified, high-purity research compounds with complete analytical records and proper cold-chain handling. In a market where trust was eroded by quality failures and abrupt closures without warning, the response is not a marketing claim — it is a verifiable record tied to a specific batch.
What products did Peptide Sciences carry?
Peptide Sciences maintained over 190 SKUs across multiple research categories: growth hormone secretagogues (ipamorelin, CJC-1295 DAC and no-DAC variants, sermorelin, hexarelin, GHRP-2, GHRP-6), metabolic peptides (GLP-1 receptor agonists, tirzepatide, semaglutide), tissue repair compounds (BPC-157, TB-500, healing factors), longevity peptides (epitalon, GHK-Cu, NAD+ precursors), and cognitive research compounds (selank, semax variants).
Onward Aminos covers the high-frequency research categories from that catalog with independently verified compounds: BPC-157, TB500, GHK-Cu, Ipamorelin, GLP-1, Sermorelin Acetate, CJC-1295 NO DAC, Epitalon, and NAD+ are all in the active catalog. The full catalog is available at Browse all compounds.
The 64-compound focus relative to Peptide Sciences' 190 allows deeper quality investment per compound — independent testing, endotoxin screening, and cold-chain logistics applied to every product rather than selectively.
Is Peptide Sciences coming back?
There is no indication of planned reopening. The domain serves a static shutdown notice with no timeline, no contact information for future updates, and no indication the closure is temporary.
The regulatory conditions that created the risk environment Peptide Sciences was operating in — FDA enforcement activity, proposed SAFE Drugs Act authority expansion, resolution of the GLP-1 shortage exemption — have not reversed. The conditions for reopening do not appear to be approaching.
Researchers should plan around permanent alternatives. This means qualifying new suppliers now, validating compound quality through independent testing, and establishing backup supply relationships to prevent single-point-of-failure exposure in ongoing research programs.
The Peptide Sciences closure carries a broader lesson about research supply chain design. A supplier generating $7.4 million per month in revenue disappeared overnight without warning. Supply chains built around a single vendor — regardless of how established they appear — carry inherent fragility in an industry undergoing rapid regulatory transformation. Maintaining diversified supplier relationships, preserving your own COA and batch number records independent of any vendor's systems, and staying current on regulatory developments are the effective mitigation strategies. Research continuity depends on operational redundancy, not brand loyalty.
All compounds referenced in this article are research chemicals intended for laboratory and scientific research purposes only. Onward Aminos does not sell products intended for human consumption. Researchers are responsible for ensuring compliance with all applicable local, state, and federal regulations governing the purchase and use of research materials.